Martindale Pharma’s Noyada, a medication that targets heart conditions in children, has been approved for early access in France due to an ATU de’ Cohorte (Temporary Authositaion for Use) programme
Noyada is an oral liquid version of captopril and is used in the treatment of paediatric chronic heart failure and Type 1 Diabetic nephropathy, according to UK-based pharmaceutical company, Matindale Pharma.
Martindale Pharma has also started the process to seek Marketing Authorisation Approval for Noyada in France.
Noyada is the only approved oral liquid formulation of captopril in Europe and has been available in the UK for two years, according to Martinale Pharma.
Cevidra Laboratories, a French-based pharmaceutical company which specialises in ATU programmes will distribute Noyada in France.
“We are delighted to be able to provide this much needed oral liquid version of captopril through the ATU de’ Cohorte programme in France with Cevidra.”
Noyada will be supplied under a specific protocol of therapeutic use which forms part of the ATU de’ Cohorte programme. The process involves specialist physicians identifying suitable patients for Noyada and enrolling them in a registry-style programme.